Meta-analysis of the Efficacy and Safety of Rivaroxaban Versus Enoxaparin for Deep Vein Thrombosis after Hip Arthroplasty
Abstract
thrombosis after hip arthroplasty. Methods: Computer search of randomized controlled trials (RCTs) of rivaroxaban and enoxaparin for NVAF
published in PubMed, CNKI, Wanfang Data Knowledge service platform, VIP Web and the full-text database of Chinese medical journals, and
the search time was from database establishment to April 2024. The test group was treated with rivaroxaban, and the control group was treated
with enoxaparin. The Meta-analysis was performed in RevMan 5.4. Results: 13 RCTs were included, including 14236 patients. The results of
the Meta-analysis showed that, Total incidence of thromboembolic events in the test group [OR = 0.58, 95%CI(0. 52, 0.81), P <0.0002], the
incidence of ischemic stroke [OR = 0.50, 95%CI(0. 32, 0.79), P=0.04], the incidence of total bleeding events [OR =0.52, 95%CI(0.29, 0.81),
P=0.002], incidence of serious bleeding events [OR = 0.6 3, 95%CI(0. 39, 0.81), P=0.0002] was lower than that in the control group; Comparison of adverse effects in 2 groups, Not show a statistically significant difference [OR =0.61, 95%CI(0.41, 1.29), P=0.26]. Conclusion: The
efficacy and safety of rivaroxabin for deep vein thrombosis after hip replacement.
Full Text:
PDFReferences
[1] Liu Chunfeng, Shi Hongwei, Ma Tengfei, etc. Effect of enoxaparin in preventing postoperative deep vein thrombosis of lower limbs
in patients with severe craniocerebral injury [J]. Transportation Medicine, 2024, 38(02):135-137. DOI:10.19767/j.cnki.32-1412
.2024.02.006.
[2] Sun Hongwei. Efficacy of sulfa sodium and enoxaparin in patients with unstable angina and influence on coagulation index [J]. China
Practical Medicine, 2023, 18(08):108-111. DOI:10.14163/j.cnki.11-5547/r. 2023.08. 032.
[3] Wang Di, Zhu Renjia, Liu Rujun, et al. Enoxaparin in the prophylaxis of deep vein thrombosis in the lower limbs after knee arthroplasty
[J]. Drug product Evaluation, 2023, 20(03):376-379. DOI:10.19939/j.cnki.1672-2809.2023.03.30.
[4] Chen Yuping, Wen Yinghong, Qi Yun. Effect of rivaroxaban anticoagulation on deep vein thrombosis in the lower limbs after knee arthroplasty [J]. Journal of PLA Medicine, 2024, 49 (11): 1302-1310.
[5] Zhong Liming. Efficacy and safety of rivaroxaban for the prevention of deep vein thrombosis in the lower limbs after hip arthroplasty [J].
Clinical rational drug use, 2024, 17(07):82-84. DOI:10.15887/j.cnki.13-1389/r. 2024.07. 023.
[6] Yang Yifan, Xu Feng. Evaluation of the effect of rivaroxaban in preventing lower extremity deep vein thrombosis in patients after total
hip arthroplasty [J]. The Electronic Journal of Modern Medicine and Health Research, 2022, 6 (11): 66-69.
[7] Feng Xiaohui. Analysis of the effect of rivaroxaban and low molecular weight heparin in the prevention of lower limb venous thrombosis after arthroplasty [J]. Straits Pharmaceutical Sciences, 2019, 31 (01): 214-215.
[8] Zhou Weina, Zhang Yi, Cao Xiangyu, et al. Effect of oral rivaroxaban in preventing lower limb deep vein thrombosis after nilateral total
hip arthroplasty [J]. Shandong Pharma, 2017, 57 (44): 95-97.
DOI: http://dx.doi.org/10.70711/mhr.v2i5.6286
Refbacks
- There are currently no refbacks.
